Key Insights

Highlights

Success Rate

76% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

14.6%

7 terminated out of 48 trials

Success Rate

75.9%

-10.6% vs benchmark

Late-Stage Pipeline

6%

3 trials in Phase 3/4

Results Transparency

32%

7 of 22 completed with results

Key Signals

7 with results76% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (11)
P 1 (8)
P 2 (16)
P 3 (3)

Trial Status

Completed22
Recruiting7
Unknown7
Terminated7
Active Not Recruiting3
Withdrawn2

Trial Success Rate

75.9%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (48)

Showing 20 of 20 trials
NCT03595813Not ApplicableCompleted

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

NCT03091192Phase 3Active Not Recruiting

Savolitinib vs. Sunitinib in MET-driven PRCC.

NCT07481851Recruiting

Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients

NCT03288545Phase 1Terminated

A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

NCT06680089Phase 2RecruitingPrimary

CD70-targeted immunoPET Imaging of Kidney Cancer

NCT04579380Phase 2Active Not Recruiting

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

NCT06353906Phase 2RecruitingPrimary

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

NCT06676527Recruiting

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

NCT05935748Phase 2Terminated

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NCT06237920Phase 2RecruitingPrimary

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NCT04442724Not ApplicableRecruiting

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

NCT03081858Phase 1Completed

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT05887245Active Not Recruiting

Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy

NCT03219333Phase 2Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT05899361Not ApplicableRecruiting

A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

NCT03636256Phase 1Completed

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

NCT03458598Not ApplicableCompleted

Pre-Operative Single Shot Rectus Sheath Block

NCT04630483Withdrawn

Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery

NCT05308771Not ApplicableUnknown

To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery

NCT05135520Not ApplicableUnknownPrimary

Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen

Scroll to load more

Research Network

Activity Timeline